4.5 Article

Up-regulation of STRA6 predicts poor prognosis and contributes to oxaliplatin resistance in colorectal cancer

Journal

PATHOLOGY RESEARCH AND PRACTICE
Volume 243, Issue -, Pages -

Publisher

ELSEVIER GMBH
DOI: 10.1016/j.prp.2023.154352

Keywords

Colorectal cancer; STRA6; Proliferation; Oxaliplatin; Chemoresistance

Categories

Ask authors/readers for more resources

This study found that the signaling receptor and transporter STRA6 is highly up-regulated in colorectal cancer (CRC) and promotes CRC cell proliferation. It was also discovered that STRA6 suppresses apoptosis by controlling BCL2 expression, leading to resistance to LOHP treatment in CRC. These findings demonstrate that STRA6 is a potential prognostic factor and oncogene in CRC by promoting tumor growth and chemoresistance.
Signaling receptor and transporter of retinol STRA6 (STRA6) plays a primary role in transporting retinol. Several studies have reported that STRA6 is involved in several pathways related to tumorigenesis and progression. However, the exact functions and mechanisms of STRA6 in colorectal cancer (CRC) remain unclear. In our work, STRA6 was highly up-regulated in CRC and promoted the proliferation of CRC cells. Additionally, we discovered that STRA6 suppresses apoptosis partly by controlling BCL2 expression, which in turn causes CRC to become resistant to LOHP treatment. Our study demonstrates that STRA6 is a potential prognostic factor and oncogene in CRC by promoting CRC growth and chemoresistance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available